Patient characteristics
| Characteristic | n | % |
| Age, median (range) | 56 (38–71) | |
| Histology | ||
| High-grade serous carcinoma | 15 | 100.0 |
| Initial FIGO stage | ||
| IIIB | 3 | 20.0 |
| IIIC | 7 | 46.7 |
| IVA | 3 | 20.0 |
| IVB | 2 | 13.3 |
| BRCA status | ||
| Mutant | 7 | 46.7 |
| Wild-type | 8 | 53.3 |
| HRD status | ||
| HRD positive | 8 | 53.3 |
| HRD unknown | 7 | 46.7 |
| Neoadjuvant chemotherapy | ||
| Number of patients receiving chemotherapy | 15 | 100.0 |
| Number of chemotherapy cycles, median (range) | 5 (4–7) | |
| Number of patients receiving bevacizumab | 6 | 40.0 |
| Number of bevacizumab cycles, median (range) | 4 (4–6) | |
| Mean duration of neoadjuvant chemotherapy, days (SD) | 91 (28) | |
| Mean duration from last neoadjuvant chemotherapy to IDS, days (SD) | 39 (17) | |
| IDS details | ||
| Mean operative time, minutes (SD) | 135 (32) | |
| Post-operative pathological staging | ||
| Tumor limited to one ovary, ypT1a | 1 | 6.6 |
| Microscopic extrapelvic involvement, ypT3a | 1 | 6.6 |
| Macroscopic metastasis beyond the pelvis ≤2 cm, ypT3b | 8 | 53.3 |
| Macroscopic metastasis beyond the pelvis >2 cm, ypT3c | 5 | 33.3 |
| Complete peritoneal debulking | 11 | 73.3 |
| ICG fluorescence microscopy | ||
| Mean number of ICG bolus per patient, n (SD) | 1.6 (0.5) | |
| Mean intraoperative fluorescence time per bolus, minutes (SD) | 3.59 (1.39) | |
| Mean fluorescence time per patient, minutes (SD) | 5.74 (2.4) | |
| Number of additional suspect peritoneal samples per patient, n (SD) | 2.6 (1.12) | |
| Survival outcomes | ||
| Relapse | 7 | 46.7 |
| Mean PFS, months (95% CI) | 34.2 (27.1 to 41.4) | |
| Death | 3 | 20 |
| Mean OS, months (95% CI) | 42.4 (37.1 to 47.7) | |
| Mean follow-up, months (95% CI) | 36.6 (32.2 to 40.9) | |
BRCA, BReast CAncer gene; CI, confidence interval; FIGO, International Federation of Gynecology and Obstetrics; HRD, homologous recombination deficiency; ICG, indocyanine green; IDS, interval debulking surgery; OS, overall survival; PFS, progression-free survival.